APA (7th ed.) Citation

Ryota Murata, Hiroshi Watanabe, Hiroto Nosaki, Kento Nishida, Hitoshi Maeda, Motohiro Nishida, & Toru Maruyama. (2022). Long-Acting Thioredoxin Ameliorates Doxorubicin-Induced Cardiomyopathy via Its Anti-Oxidative and Anti-Inflammatory Action. MDPI AG.

Chicago Style (17th ed.) Citation

Ryota Murata, Hiroshi Watanabe, Hiroto Nosaki, Kento Nishida, Hitoshi Maeda, Motohiro Nishida, and Toru Maruyama. Long-Acting Thioredoxin Ameliorates Doxorubicin-Induced Cardiomyopathy via Its Anti-Oxidative and Anti-Inflammatory Action. MDPI AG, 2022.

MLA (9th ed.) Citation

Ryota Murata, et al. Long-Acting Thioredoxin Ameliorates Doxorubicin-Induced Cardiomyopathy via Its Anti-Oxidative and Anti-Inflammatory Action. MDPI AG, 2022.